{"id":"12558501-c3a9-52ba-a4e9-0ed0cd3170cf","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:ss-apt2-elisa-qualified","predicate":"has_contextual_experimental_result","statement":"The study reports a reduced LYPLA2 ELISA signal as reduced APT2 activity; the described assay does not establish catalytic turnover.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"6edf0c15-c518-5326-93be-f496c86df456","mechanism_event_label":"ss-apt2-elisa-qualified","subject":{"id":"6410ac1a-e95f-550f-955a-6725a3765ee3","slug":"solasonine","display_name":"Solasonine","entity_type_key":"small_molecule"},"object":{"id":"d55d948d-1dac-50fd-9a9e-9dc767440b77","slug":"human-lypla2-elisa-signal","display_name":"LYPLA2 antibody ELISA signal in human cell supernatants","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"6edf0c15-c518-5326-93be-f496c86df456","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:ss-apt2-elisa-qualified","event_type":"experimental_result","label":"ss-apt2-elisa-qualified","description":"The study reports a reduced LYPLA2 ELISA signal as reduced APT2 activity; the described assay does not establish catalytic turnover.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6410ac1a-e95f-550f-955a-6725a3765ee3","slug":"solasonine","display_name":"Solasonine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d55d948d-1dac-50fd-9a9e-9dc767440b77","slug":"human-lypla2-elisa-signal","display_name":"LYPLA2 antibody ELISA signal in human cell supernatants","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f2ffef5b-5457-50a8-b787-b8f24430f610","slug":"lypla2","display_name":"LYPLA2","entity_type_key":"protein"},"role":"antibody assay analyte","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Human NOZ and GBC-SD gallbladder cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Cell-supernatant ELISA; 0-50 ng/mL standards, anti-LYPLA2 plates, LYPLA2-HRP conjugate, H2O2/TMB chromogen, 450 nm readout with 630 nm reference. Cellular drug duration described as 48 hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_locator","value_text":"Figure 5C versus Methods 2.17 ELISA Assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"https://doi.org/10.1002/ptr.70245","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6ca2282d-a551-5d16-943c-c18a021bcb8f","evidence_kind":"source_excerpt","locator":"Lines 105-111","start_line":105,"end_line":111,"excerpt":"The study reports a reduced LYPLA2 ELISA signal as reduced APT2 activity; the described assay does not establish catalytic turnover.\nprimary_references: https://doi.org/10.1002/ptr.70245\nprimary_locator: Figure 5C versus Methods 2.17 ELISA Assay.\norganism: Human\nexperimental_model: Human NOZ and GBC-SD gallbladder cancer cells\nexposure: Cell-supernatant ELISA; 0-50 ng/mL standards, anti-LYPLA2 plates, LYPLA2-HRP conjugate, H2O2/TMB chromogen, 450 nm readout with 630 nm reference. Cellular drug duration described as 48 hours.\nlimitations: Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","model_system":"Human NOZ and GBC-SD gallbladder cancer cells","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curator paraphrase, not a publisher quotation. Methodological inference is explicitly identified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"15a55d0b-bd44-54e4-9080-5526d1a9744d","stable_key":"import-d71929ae-ed38-52ed-b512-f92b9b148b71","title":"APT2, STAT3 and GPX4: opposing branches and assay qualification","document_type":"imported_text","citation_label":"Primary observations: 10.1038/s41467-025-56344-5 and 10.1002/ptr.70245; selected full-text review 2026-09-20.","file_path":"","sha256":"6fd94803c436074e7b2c15e9a817e751c3d95f6fe1d35a4af63ab641a8f33fe0","revision_id":"d59d5472-18d2-5feb-bc2e-529ceda00956","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}